GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Inventories, Raw Materials & Components

Rigel Pharmaceuticals (STU:RI2A) Inventories, Raw Materials & Components : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Inventories, Raw Materials & Components?

Rigel Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Mar. 2024 was €0.0 Mil.

Rigel Pharmaceuticals's annual raw materials declined from Dec. 2021 (€4.6 Mil) to Dec. 2022 (€4.3 Mil) and declined from Dec. 2022 (€4.3 Mil) to Dec. 2023 (€0.0 Mil).


Rigel Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for Rigel Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Inventories, Raw Materials & Components Chart

Rigel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.55 4.30 -

Rigel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.45 6.35 - - -

Rigel Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines